Form 8-K - Current report:
SEC Accession No. 0001104659-25-029065
Filing Date
2025-03-28
Accepted
2025-03-28 07:35:03
Documents
15
Period of Report
2025-03-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2510712d1_8k.htm   iXBRL 8-K 23092
2 EXHIBIT 99.1 tm2510712d1_ex99-1.htm EX-99.1 86369
6 GRAPHIC tm2510712d1_ex99-1img001.jpg GRAPHIC 4369
  Complete submission text file 0001104659-25-029065.txt   301528

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA lvtx-20250328.xsd EX-101.SCH 3039
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE lvtx-20250328_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lvtx-20250328_pre.xml EX-101.PRE 22375
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2510712d1_8k_htm.xml XML 3668
Mailing Address YALELAAN 62 UTRECHT P7 3584 CM
Business Address YALELAAN 62 UTRECHT P7 3584 CM 31 6 3000 3035
LAVA Therapeutics NV (Filer) CIK: 0001840748 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40241 | Film No.: 25781496
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)